The Koebner phenomenon has been described following a surgical procedure in various dermatoses, including psoriasis, vitiligo, and lichen planus. • Koebnerization in hidradenitis suppurativa (HS) has recently been observed in patients in whom new lesions developed as a result of trauma.
Novel Insights• The Koebner phenomenon following the scarring process on a cesarean section site has not previously been reported. • Avoidance of external trauma could be included in general measures of HS treatment. • Disease recurrence should be considered for patients treated with surgical excision of HS lesions.
AbstractHidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin disorder of the hair follicle. Trauma, mechanical pressure, or friction could have an important role in the pathogenesis of HS. We present a patient with HS who de-
Background
Paradoxical psoriasis (PP) has been mainly described in patients receiving tumor necrosis factor-α (TNFα)-inhibitors for inflammatory bowel disease or psoriasis vulgaris, while such data in the context of hidradenitis suppurativa (HS) are scarce. The purpose of this study was to demonstrate the course of PP and the underlying HS upon switching from adalimumab to a biologic agent targeting the interleukin (IL)-17/IL-23 axis.
Methods
The electronic medical database of the outpatient department for HS of a tertiary hospital for skin diseases was searched to identify patients with moderate to severe HS under treatment with adalimumab, who developed PP and were switched to biological therapy with an IL-17 or IL-23 inhibitor between February 2016 and January 2022. Disease assessment scores were evaluated at baseline, at time of PP development as well as six and twelve months thereafter.
Results
Among the 83 patients who received adalimumab the treatment of HS between February 2016 and January 2022, 10 patients (12%) developed paradoxical psoriasiform skin reactions after a median time of seven (range, 2-48) months. There were four females (40%) and six males (60%) with a median age of 42,5 (range, 33-56) years. Five patients presented with plaque psoriasis and five with palmoplantar pustulosis, while four had intertriginous and three nail involvement. In most of the patients the HS responded well to adalimumab at onset of PP. Eight patients were changed to secukinumab, one to ustekinumab and one to rizankizumab. The HS further improved in all but two patients, one receiving secukinumab and one receiving rizankizumab. In addition, all patients achieved improvement of PP.
Conclusion
Despite the small number of patients, this study provides support that patients with adalimumab-induced PP may benefit from biologics targeting IL-17/IL-23 axis. Further studies are needed, to establish the optimal therapeutic strategy of the anti-TNFα-induced PP in the context of HS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.